Medical Innovation
Americans today are benefiting from medical developments and discoveries that took shape almost two decades ago. On average, the travel time of an experimental drug from the lab to patients is 12 to15 years. Lawmakers need to realize the considerable impact that federal policies can have on maintaining the future of drug discovery and innovation.
All Americans, especially the aging, want the best therapies for life-threatening diseases and disabling and chronic conditions. A core goal of the Alliance for Aging Research is to encourage policies which will lead to newer and better treatments to improve the health and independence of Americans as they age.
Related Publications
-
Press ReleaseExperts Call for Investing in Longevity Science to Bolster Older Americans' Contributions
With the nation’s economy uppermost in many Americans’ minds, the Alliance for Aging Research explores the economic benefits from increased investment in longevity science in its most recent podcast series. The podcast series is part of the Alliance’s SAGE Crossroads website, a forum that explores emerging issues of human aging and longevity. -
DocumentThe Burden and Future Implications of
Adult Visual Disorders in the United States
In an Alliance for Aging Research, National Alliance for Eye and Vision Research (NAEVR) joint briefing, David Rein, PhD, presented on the current economic burden of vision loss and the potential future impact. His slides are available here. -
DocumentAge-Related Maculopathy:
What it is, what we know, what we need to learn
In an Alliance for Aging Research, National Alliance for Eye and Vision Research (NAEVR briefing, Dr. Michael Gorin presented on age-related maculopathy, an eye disease that affects millions of Americans. His presentation slides are available here.
